Methods and compositions for treating allergic reactions

a technology for allergic reactions and compositions, applied in the direction of drug compositions, peptide/protein ingredients, immunological disorders, etc., can solve the problems of methotrexate, a large inherent toxicity, and the inability to tolerate long-term use,

Inactive Publication Date: 2005-03-17
IMMUNEX CORP
View PDF8 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While suppression of symptoms is achieved to a degree sufficient to avoid death, urgent medical visits, disturbed sleep, and days lost from work are typically unavoidable.
For example, systemically administered glucocorticosteroids are potent antiasthmatics; however, the symptoms of the disease are only temporarily suppressed and this is at the cost of well-known side effects, including osteoporosis, weight gain, hypertension, and diabetes (Barnes, P. J., New Eng. J. Med. 321:1517 (1989)).
However, methotrexate, while frequently substituting for toxic doses of corticosteroids, has significant inherent toxicity.
Furthermore, it does not eliminate the need for periodic corticosteroids.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating allergic reactions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0050] This example describes the use of soluble IL-1 receptor to reduce the cutaneous allergic reactions following the intradermal administration of antigen.

[0051] Early and late phase responses have been observed following bronchial challenge with such antigens as ragweed pollen and house dust. Importantly, these responses in lung tissue correspond in time to the early and late phase reactions in skin following intradermal challenge with similar antigens (See Dolovich, J. and D. C. Little, J. Allergy Clin. Immunol. 49:43 (1972); See also Solley, G. O. et al., J. Clin. Invest. 58:408 (1976)). Skin reactivity to allergen, especially the Late Phase Reaction (LPR) skin test is believed to be predictive of events occurring in the lungs of asthmatics.

[0052] The LPR skin test is performed by interadermally injecting subjects on the forearm with test solution. The test solution contains the challenging antigen. Controls receive test solution without challenging antigen. The injection si...

example 2

[0061] This example describes the use of soluble IL-1 receptor to reduce the LPR following conjunctival provocation with antigen.

[0062] Ocular involvement is common in allergic conditions. It can be the result of systemic allergic symptoms or, indeed, the main focus of allergic disease.

[0063] With respect to specific ocular allergies, allergic rhinoconjunctivitis, atopic keratoconjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis, and contact allergy have been identified as the primary types. The most commonly seen form of ocular allergy is the red itchy eyes that accompany allergic rhinitis during the allergy season.

[0064] Usually ocular symptoms are overshadowed by nasal or respiratory symptoms. However, in some cases the ocular symptoms predominate. Patients typically complain of red, swollen, itchy eyes, and scant mucous discharge. Itching is an important symptom for ocular allergy since most patients with allergy have itching, and very few other ocular condit...

example 3

[0077] This example describes the use of soluble IL-1 receptor to reduce the LPR in nasal tissue following inhalation of antigen.

[0078] Patients with allergic rhinitis often have immediate symptoms after antigen challenge (the early phase response), followed several hours later by a recurrence of symptoms (the late-phase response). This example involves a controlled study of asymptomatic subjects in the pollen-free winter months.

[0079] Sixteen patients with seasonal allergic rhinitis due to grass or ragweed pollens are selected. All subjects have a positive intradermal skin test to 10 PNU (protein nitrogen units) or less of antigen extract, and all have previously had a dual response (early and late) to nasal challenge with antigen.

[0080] Ragweed and mixed-grass pollen extracts (timothy, orchard, June and meadow grass in a ratio of 3:2:3:2) are purchased from Greer Laboratories (Lenoir, N.C.); lactated Ringer's solution and oxymetazoline hydrochloride (Afrin, Schering, Kenilworth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
solubleaaaaaaaaaa
Login to view more

Abstract

Methods and compositions for treating allergic reactions, including cutaneous, ocular, nasal and bronchial allergic disease, are disclosed. Interleukin-1 and Tumor Necrosis Factor receptors, and analogues thereof, are employed which bind the respective effector competitively and thereby suppress allergic reactions.

Description

TECHNICAL FIELD [0001] The present invention relates to methods and compositions for treating allergic reactions, and, more particularly, for treating bronchial asthma, rhinitis, rhinoconjunctivitis, conjunctivitis, and dermatitis. BACKGROUND OF THE INVENTION [0002] An allergic reaction is any abnormal or altered reaction to an antigen (or “allergen”). Typically such a reaction is characterized by hypersensitivity of the body to specific substances, whether protein, lipid or carbohydrate in nature. Allergic reactions may be local, e.g. contact dermatitis, or systemic, e.g. anaphylaxis. [0003] Among allergic diseases, bronchial asthma is one of the most significant. In most urban hospitals, it is the leading cause of admission of children. Current medical practice accepts asthma in afflicted individuals to be an unavoidable, incurable illness. While suppression of symptoms is achieved to a degree sufficient to avoid death, urgent medical visits, disturbed sleep, and days lost from wo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/15A61K31/575A61K38/00A61K38/17A61P29/00A61P37/08
CPCA61K38/1793A61K31/573A61K2300/00A61P29/00A61P37/08
Inventor MULLARKEY, MICHAEL F.
Owner IMMUNEX CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap